Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial

Murtola T. J., GÜREL B., Umbehr M., Lucia M. S., Thompson I. M., Goodman P. J., ...More

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, vol.25, no.3, pp.463-469, 2016 (SCI-Expanded) identifier identifier identifier


Background: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA. Here, we studied these associations in the PCPT finasteride arm.